Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4

References

• Arinc E, Arslan S, Bozcaarmutlu A. (2007). Effects of diabetes on rabbit kidney and lung CYP2E1 and CYP2B4 expression and drug metabolism and potentiation of carcinogenic activity of N-nitrosodimethylamine in kidney and lung. Food Chem Toxicol 45:107–18
   PubMed Web of Science ®Google Scholar
• Boridy S, Le PU, Petrecca K, et al. (2014). Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells. Cell Death Dis 5:1--12
   Web of Science ®Google Scholar
• Carrillo JA, Christensen M, Ramos SI, et al. (2000). Evaluation of caffeine as an in vivo probe for CYP1A2 usingmeasurements in plasma, saliva, and urine. Ther Drug Monit 22:409–17
   PubMed Web of Science ®Google Scholar
• Dinger J, Meyer MR, Maurer HH. (2014). Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett 230:28–35
   PubMed Web of Science ®Google Scholar
• Faber MS, Jetter A, Fuhr U. (2005). Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125–34
   PubMed Web of Science ®Google Scholar
• Faust K, Gehrke S, Yang Y, et al. (2009). Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci 10:109
   PubMed Web of Science ®Google Scholar
• Fontana E, Dansette PM, Poli SM. (2005). Cytochrome p450 enzymes mechanism based inhibitors:common sub-structures and reactivity. Current Drug Metab 6:413–54
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Kobayashi T, Tachibana K, et al. (2006). Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab Pharmacokinet 21:501–5
   PubMed Web of Science ®Google Scholar
• Goldstein JA. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349–55
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. (2007). The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 35:1–8
   PubMed Web of Science ®Google Scholar
• Grimm SW, Einolf HJ, Hall SD, et al. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355–70
   PubMed Web of Science ®Google Scholar
• Heeyeon K, Hyun KC, Tae CJ, et al. (2013). Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes. Food Chem Toxicol 51:33–7
   PubMed Web of Science ®Google Scholar
• Johnson EF, Connick JP, Reed JR, et al. (2014). Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges. Drug Metab Dispos 42:9–22
   PubMed Web of Science ®Google Scholar
• Kim DY, Park JW, Jeoung D, et al. (2009). Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur J Pharmacol 612:98–105
   PubMed Web of Science ®Google Scholar
• Li J, Gödecke T, Chen SN, et al. (2011). In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. Xenobiotica 41:1021–30
   Web of Science ®Google Scholar
• Min S, Yu T, Tonggui D, et al. (2014). Inhibitory effects of celastrol on rat liver cytochrome P450 1A2,2C11, 2D6, 2E1 and 3A2 activity. Fitoterapia 92:1–8
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246–55
   PubMed Web of Science ®Google Scholar
• Qiu D, Kao PN. (2003). Immunosuppressive and ant-i inflammatory mechanism of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f Drugs R.D 4:1–18
   Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver micros omes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23
   PubMed Web of Science ®Google Scholar
• Shimada T, Mimura M, Inoue K, et al. (1997). Cytochrome P450-dependent drug oxidation activities in live rmicrosomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401–8
   PubMed Web of Science ®Google Scholar
• Slaughter RL, Edwards DJ. (1995). Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 29:619–24
   PubMed Web of Science ®Google Scholar
• Yang H, Chen D, Cui QC, et al. (2006). Celastrol, a triterpene extracted from the Chinese “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66:4758–65
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu Z, Tolosa E, et al. (1998). Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 40:139–49
   PubMed Web of Science ®Google Scholar
• Ye LH, He XX, Kong LT, et al. (2014). Identification and characterization of potent CYP2D6 inhibitors in lotus leaves. J Ethnopharmacology 153:190–6
   PubMed Web of Science ®Google Scholar
• Usia T, Iwata H, Hirastuka A, et al. (2006). CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants. Phytomedicine 13:67–73
   PubMed Web of Science ®Google Scholar
• Zhang J, Li CY, Xu MJ, et al. (2012). Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats. J Ethnopharmacology 144:195–200
   PubMed Web of Science ®Google Scholar
• Zuber R, Anzenbacherová E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189–98
   PubMed Web of Science ®Google Scholar